Amarin reported preliminary fourth-quarter product sales of approximately $120 million, exceeding consensus estimates of $110 million by 9%. For the full fiscal 2025 year, preliminary sales reached $480 million, beating forecasts of $455 million by 5.5%. Following the release of these preliminary figures, Amarin’s shares climbed 17% during intraday trading, reflecting investor confidence in the company’s accelerated revenue trajectory driven by VASCEPA®/VAZKEPA® prescriptions across key markets.

The company generated positive operating cash flow of $10 million in Q4 2025, marking its first quarterly cash-flow breakeven since launching its expanded cardiovascular franchise. Management highlighted that ongoing efficiency measures—focused on streamlining manufacturing operations and reducing SG&A expenses—are on track to deliver $25 million in annualized cost savings by mid-2026. These savings are expected to bolster free cash flow and fund strategic investments in commercial expansion without diluting shareholders.

Amarin underscored significant progress in its global rollout of its icosapent ethyl franchise. In 2025, the company secured an exclusive license and supply agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 European markets, where patent protection extends until 2039. As of January 2026, VASCEPA/VAZKEPA is commercially available in more than 20 countries, and cumulative prescriptions have surpassed 25 million worldwide. Backed by robust REDUCE-IT trial data involving 8,179 patients and demonstrating a 25% relative reduction in cardiovascular events versus placebo, the therapy remains the leading oral option in payor-driven step-therapy protocols for patients with severe hypertriglyceridemia and established cardiovascular risk.